|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004083,
umls-concept:C0022646,
umls-concept:C0035015,
umls-concept:C0054946,
umls-concept:C0178539,
umls-concept:C0205178,
umls-concept:C0205210,
umls-concept:C0332448,
umls-concept:C0450127,
umls-concept:C0522536,
umls-concept:C1274040,
umls-concept:C1417326,
umls-concept:C1548437,
umls-concept:C1706319,
umls-concept:C1882923
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2005-8-12
|
|
pubmed:abstractText |
We undertook a study to ascertain the relationship between the presence of CD20-positive B-lymphocytes in renal allografts undergoing acute cellular rejection and graft survival. We identified 27 patients transplanted between January 1, 1998 and December 31, 2001, with biopsy-proven Banff 1-A or Banff 1-B rejection in the first year after transplantation, and stained the specimens for CD20 and C4d. At least 4 years of follow-up data were available for each patient studied. Six patients had CD20-positive B-cell clusters in the interstitium, and 21 patients were negative for CD20 infiltrates. The CD20-positive group was significantly more likely to have steroid-resistant rejection and reduced graft survival compared to CD20-negative controls. This study supports prospective identification of CD20-positive B-cell clusters in biopsy-proven rejection and offers a therapeutic rationale for a trial of monoclonal anti-CD20 antibody in such patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1600-6135
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2248-52
|
|
pubmed:dateRevised |
2007-2-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16095505-Adult,
pubmed-meshheading:16095505-Aged,
pubmed-meshheading:16095505-Antibodies, Monoclonal,
pubmed-meshheading:16095505-Antigens, CD20,
pubmed-meshheading:16095505-B-Lymphocytes,
pubmed-meshheading:16095505-Biopsy,
pubmed-meshheading:16095505-Complement C4b,
pubmed-meshheading:16095505-Female,
pubmed-meshheading:16095505-Follow-Up Studies,
pubmed-meshheading:16095505-Graft Rejection,
pubmed-meshheading:16095505-Graft Survival,
pubmed-meshheading:16095505-Humans,
pubmed-meshheading:16095505-Immunohistochemistry,
pubmed-meshheading:16095505-Immunosuppressive Agents,
pubmed-meshheading:16095505-Kidney,
pubmed-meshheading:16095505-Kidney Transplantation,
pubmed-meshheading:16095505-Male,
pubmed-meshheading:16095505-Middle Aged,
pubmed-meshheading:16095505-Peptide Fragments,
pubmed-meshheading:16095505-Retrospective Studies,
pubmed-meshheading:16095505-Time Factors,
pubmed-meshheading:16095505-Transplantation, Homologous,
pubmed-meshheading:16095505-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts.
|
|
pubmed:affiliation |
Division of Nephrology, Department of Medicine, University of Alabama, Birmingham, Alabama, USA. bhippen@uab.edu
|
|
pubmed:publicationType |
Journal Article
|
